pyrazines has been researched along with Bone Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, B; Wang, Y | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Malard, F; Mohty, B; Mohty, M; Moreau, P; Savani, B; Terpos, E | 1 |
| Grandjean, C; Horger, M; Oehrlein, K; Schulze, M; Spira, D; Weisel, K; Zago, M | 1 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
| Anagnostopoulos, A; Athanasiou, E; Bougiouklis, D; Kaloyannidis, P; Palladas, P; Papadopoulou, A; Paraskeva, A; Yannaki, E; Yiangou, M | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H | 1 |
| Hino, N; Omura, H; Tanaka, T; Yamasaki, R | 1 |
| Berglund, J | 1 |
| Terpos, E; Tricot, G; Zangari, M; Zhan, F | 1 |
| Morgan, G | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Joshua, DE | 1 |
| Croucher, P; Dimopoulos, MA; Sezer, O; Terpos, E | 1 |
| Roodman, GD | 1 |
| Courtney, CL; Dominick, MA; Kim, SN; Walsh, KM; Watkins, JR | 1 |
5 review(s) available for pyrazines and Bone Diseases
| Article | Year |
|---|---|
The effects of bortezomib on bone disease in patients with multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evidence-Based Medicine; Humans; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Pyrazines; Signal Transduction | 2014 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Impact of bortezomib on bone health in myeloma: a review of current evidence.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Osteogenesis; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Myeloma bone disease and proteasome inhibition therapies.
Topics: Bone Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2007 |
1 trial(s) available for pyrazines and Bone Diseases
| Article | Year |
|---|---|
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant | 2011 |
12 other study(ies) available for pyrazines and Bone Diseases
| Article | Year |
|---|---|
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulation; Diphosphonates; Drug Therapy, Combination; Humans; Models, Biological; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Pamidronate; Pyrazines; Reproducibility of Results; User-Computer Interface | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiation Dosage; Retrospective Studies; Risk Factors; Sclerosis; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines | 2009 |
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
Topics: Analysis of Variance; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Diseases; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Flow Cytometry; Immunohistochemistry; Inflammation; Joints; Pyrazines; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Synovial Membrane; Toll-Like Receptors; Treatment Outcome | 2010 |
Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Topics: Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2011 |
Orthopaedics: Structural support.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosphonates; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Kyphoplasty; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines | 2011 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Bone building with bortezomib.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines | 2008 |
Proliferative bone lesions in rats given anticancer compounds.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Development; Bone Diseases; Bone Marrow; Carbamates; Cell Division; Drug Combinations; Female; Glucuronates; Injections, Intravenous; Male; Pentostatin; Pyrazines; Pyridines; Rats; Rats, Inbred Strains; Trimetrexate | 1991 |